[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BPharmCatalyst Avatar @BPharmCatalyst BioPharmCatalyst

BioPharmCatalyst posts on X about $cmnd, $pmcb, $meso, $kala the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence cryptocurrencies XXXXX% stocks XXXXX% finance XXXXX%

Social topic influence $cmnd #5, $pmcb 17.65%, $meso 17.65%, $kala 11.76%, $sprc 11.76%, $vrca 11.76%, $phge 11.76%, $mndr 11.76%, $tyra 11.76%, $gels XXXXX%

Top accounts mentioned or mentioned by @artsstocks

Top assets mentioned Dawn Protocol (DAWN) Allurion Technologies, Inc. (ALUR) Janux Therapeutics, Inc. Common Stock (JANX) Sonnet BioTherapeutics Holdings, Inc. Common Stock (SONN) Immunovant, Inc. Common Stock (IMVT) CG Oncology, Inc. Common stock (CGON) Vir Biotechnology, Inc. Common Stock (VIR) Integral (ITGR) uniQure N.V. (QURE) Marblex (MBX) Regencell Bioscience Holdings Limited Ordinary Shares (RGC) ADC Therapeutics SA (ADCT) Taraxa (TARA) Praxis Precision Medicines, Inc. Common Stock (PRAX) Cooper Companies, Inc. (COO) Adaptive Biotechnologies Corporation Common Stock (ADPT) Curate (XCUR) MetaBeat (BEAT) Dyne Therapeutics, Inc. Common Stock (DYN) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Camp Network (CAMP)

Top Social Posts

Top posts by engagements in the last XX hours

"$MRSN agreed to merge with $DAWN where Day One will acquire Mersana through a tender offer and second-step merger. The deal involves an upfront payment of $XXXXX per share in cash plus up to $XXXXX per share in contingent value rights (CVRs) based on clinical regulatory and commercial milestones related to Emi-Le Mersana's B7-H4 ADC. Additionally a milestone from an existing Mersana collaboration will be issued with a total equity value of about $XXX million at closing and a total deal value up to $XXX million. $MRSN $KRRO $MGNX $MGRX $CMND $APLT $AEMD $BJDX $ABSI $LUCY See More Pre-market"
X Link 2025-11-13T13:40Z 30.5K followers, 2071 engagements

"$ALUR reported initial 12-month results from a study combining its Smart Capsule program with low-dose tirzepatide showing XX% average total weight loss and a XX% increase in lean body mass with full patient adherence and no early discontinuations $ALUR $CTNM $ESPR $CMND $KTTA $TPST $KZIA $PMBC $CLSD $ADTX See More Biotech Updates👇"
X Link 2025-11-25T21:30Z 30.5K followers, 1970 engagements

"$ $KALA $SPRC $VRCA $PHGE $CMND $PMCB $MNDR $MESO $TYRA $GELS See More Pre-market Movers"
X Link 2025-11-27T13:40Z 30.5K followers, 1586 engagements

"$ $KALA $SPRC $VRCA $PHGE $CMND $PMCB $MNDR $MESO $TYRA $GELS See More Pre-market Movers"
X Link 2025-11-28T13:40Z 30.5K followers, 2066 engagements

"$JANX announced updated interim data from its Phase 1a and Phase 1b clinical trials of JANX007 a PSMA-directed TRACTr in patients with metastatic castration-resistant prostate cancer (mCRPC). $PLRZ $JANX $NIVF $SONN $GUTS $CMND $MGRX $BNR $ARMP $MTVA See More Biotech Updates👇"
X Link 2025-12-02T21:47Z 30.5K followers, 2033 engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: BioPharmCatalyst Weekly Watchlist: Key Phase X catalysts remaining this quarter $MESO $SLS $MGTX $XOMA $BLTE $IMVT $CAPR $ERAS $CGON $CGEM"
X Link 2025-11-08T16:00Z 30.5K followers, 2062 engagements

"$NWBO will acquire contract manufacturer Advent BioServices aiming to fully integrate operations gain manufacturing assets and IP cancel 19M previously issued securities and position for operational scale-up with expected cost and efficiency synergies. $BTAI $ELMD $AZTR $VIR $MAIA $RENB See More Biotech Updates👇"
X Link 2025-08-27T20:30Z 30.5K followers, 5535 engagements

"$ITGR posted Q3 2025 revenue of $468M up X% with X% organic growth and a XX% rise in non-GAAP EPS to $XXXX while adjusted EBITDA rose XX% to $106M. However management cut the midpoint of full-year sales guidance by $16M with Q4 organic sales expected to slow sharply to -X% to +2%. Debt rose $204M to $1.19B pushing leverage to 3.0x driven by acquisitions and the 2030 convertible note offering. $VTYX $ITGR $GNPX $NLSP $IBIO $TNGX $BIOA $NMRA $RANI $LIPO See More Biotech Updates👇"
X Link 2025-10-23T20:30Z 30.5K followers, 1876 engagements

"$DRMA announced it will unveil a new brand identity for its OTC skincare business signaling a strategic shift toward direct-to-consumer science-driven innovation; the rebrand targets informed results-oriented skincare consumers and reflects the companys mission to merge scientific rigor with holistic dermatologic solutions. $PLRZ $PLRX $QURE $DRMA $CLNN $MBX $PMCB $RGC $EVFM $ADCT See More Biotech Updates👇"
X Link 2025-12-04T21:30Z 30.5K followers, 1746 engagements

"$TARA priced a $75M underwritten public offering of 13.0M shares at $XXXX each with a 30-day option to sell up to 2.0M additional shares; proceeds will support clinical development of TARA-002 and other programs with closing expected on December X 2025. $TARA $PRAX $VNDA $CAPR $IMTX $ICCM $SNSE $COO $ADPT $CYCN See More Pre-market Movers"
X Link 2025-12-05T13:40Z 30.5K followers, 1637 engagements

"$XCUR reported Phase X results for burixafor plus propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant with XXXX% achieving the primary endpoint of adequate CD34+ cell mobilization in X sessions. The rapid mobilization profile and efficacy in daratumumab-exposed patients highlight burixafors differentiated potential as a same-day mobilization agent. $XCUR $SNTI $COYA $PBM $ENSC $ENVB $VOR $ALT $BDRX $MTVA See More Pre-market Movers"
X Link 2025-12-09T13:40Z 30.5K followers, 1612 engagements

"$BEAT secured FDA 510(k) clearance for its 12-lead ECG synthesis software following a successful appeal of a prior NSE ruling. The breakthrough cable-free credit-card-sized device enables at-home clinical-grade arrhythmia assessment unlocking key growth initiatives and positioning the company to transform remote cardiac care. $BEAT $MODD $DYN $DARE $FULC $PMN $ENVB $CVKD $WOK $NIVF See More Pre-market Movers"
X Link 2025-12-10T13:40Z 30.5K followers, 1751 engagements

"$RYTM will report preliminary Phase X data for setmelanotide in Prader-Willi syndrome during a live webcast on December XX offering an early look at potential expansion of its rare disease pipeline. $MBRX $MODD $RYTM $GRI $CRBP $CMND $IBIO $CAMP $ATPC $IMRN See More Biotech Updates👇"
X Link 2025-12-10T21:30Z 30.5K followers, 2120 engagements